Healthcare provider profile · identity verified

Jill Marsh, MD

Family Practice · BIRMINGHAM, AL · NPI 1023338340

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	293	90
Atorvastatin Calcium	Atorvastatin Calcium	264	77
Gabapentin	Gabapentin	229	49
Losartan Potassium	Losartan Potassium	205	64
Metformin Hcl Er	Metformin Hcl	151	47
Levothyroxine Sodium	Levothyroxine Sodium	136	37
Potassium Chloride	Potassium Chloride	117	34
Pantoprazole Sodium	Pantoprazole Sodium	115	36
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	114	22
Hydrochlorothiazide	Hydrochlorothiazide	106	33
Carvedilol	Carvedilol	104	31
Metoprolol Succinate	Metoprolol Succinate	102	33
Mounjaro	Tirzepatide	90	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	88	28
Albuterol Sulfate Hfa	Albuterol Sulfate	83	36
Famotidine	Famotidine	83	31
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	82	31
Eliquis	Apixaban	80	14
Trazodone Hcl	Trazodone Hcl	73	24
Furosemide	Furosemide	71	31
Montelukast Sodium	Montelukast Sodium	71	27
Omeprazole	Omeprazole	66	19
Ozempic	Semaglutide	66	12
Spironolactone	Spironolactone	60	19
Rosuvastatin Calcium	Rosuvastatin Calcium	52	19
Esomeprazole Magnesium	Esomeprazole Magnesium	51	12
Lisinopril	Lisinopril	50	15
Meloxicam	Meloxicam	50	13
Fluticasone Propionate	Fluticasone Propionate	48	17
Oxycodone Hcl	Oxycodone Hcl	48	suppressed
Pravastatin Sodium	Pravastatin Sodium	46	15
Pregabalin	Pregabalin	46	11
Celecoxib	Celecoxib	44	13
Tramadol Hcl	Tramadol Hcl	44	11
Methocarbamol	Methocarbamol	42	17
Duloxetine Hcl	Duloxetine Hcl	40	15
Metformin Hcl	Metformin Hcl	40	16
Clonazepam	Clonazepam	38	suppressed
Doxepin Hcl	Doxepin Hcl	38	13
Naproxen	Naproxen	38	15
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	37	suppressed
Alendronate Sodium	Alendronate Sodium	35	suppressed
Jardiance	Empagliflozin	35	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	suppressed
Breo Ellipta	Fluticasone/Vilanterol	34	11
Prednisone	Prednisone	34	24
Allopurinol	Allopurinol	33	11
Baclofen	Baclofen	33	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	33	12
Lorazepam	Lorazepam	32	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Diclofenac Sodium	Diclofenac Sodium	27	17
Oxybutynin Chloride Er	Oxybutynin Chloride	27	suppressed
Promethazine Hcl	Promethazine Hcl	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	18
Glipizide Er	Glipizide	26	suppressed
Trospium Chloride Er	Trospium Chloride	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Propranolol Hcl	Propranolol Hcl	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Chlorthalidone	Chlorthalidone	22	suppressed
Estradiol	Estradiol	22	suppressed
Fluconazole	Fluconazole	22	16
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Mirtazapine	Mirtazapine	21	suppressed
Cephalexin	Cephalexin	19	suppressed
Diazepam	Diazepam	19	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	19	suppressed
Terbinafine Hcl	Terbinafine Hcl	19	suppressed
Torsemide	Torsemide	19	suppressed
Levemir Flexpen	Insulin Detemir	18	suppressed
Propranolol Hcl Er	Propranolol Hcl	18	suppressed
Alprazolam	Alprazolam	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Atenolol	Atenolol	16	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Gemtesa	Vibegron	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Repatha Sureclick	Evolocumab	15	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Naltrexone Hcl	Naltrexone Hcl	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Sertraline Hcl	Sertraline Hcl	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Simvastatin	Simvastatin	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Clotrimazole	Clotrimazole	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Imipramine Hcl	Imipramine Hcl	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Temazepam	Temazepam	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Azithromycin	Azithromycin	11	11
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Fosinopril Sodium	Fosinopril Sodium	11	suppressed
Naratriptan Hcl	Naratriptan Hcl	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error